Oruka Therapeutics, Inc. (ORKA) has 16 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 6 sales totalling $2.4M. Most recent filing: Sept. 15, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 15, 2026 | Goncalves Joana Chief Medical Officer | −$87,484 | 21,947 | −1% | Yes | |
|
|
||||||
| Sept. 15, 2026 filed Sept. 11, 2026 | Agarwal Arjun Senior Vice President, Finance | −$51,758 | 28,937 | −4% | Yes | |
|
|
||||||
| Sept. 15, 2026 | Klein Lawrence Otto Chief Executive Officer | −$234,681 | 2,452 | −0% | No | |
|
|
||||||
| Sept. 15, 2026 | Quinlan Paul T General Counsel | −$99,443 | 1,039 | −3% | No | |
|
|
||||||
| Sept. 15, 2026 | Sandler Laura Lee Chief Operating Officer | −$86,713 | 906 | −0% | No | |
|
|
||||||
Showing the 5 most recent of 16 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free